<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
(RULE 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
(AMENDMENT NO. 3)
ISIS PHARMACEUTICALS, INC.
------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, PAR VALUE $0.001 PER SHARE
------------------------------------------------------------------
(Title of Class of Securities)
464330 10 9
------------------------------------------------------------------
(Cusip Number)
HANS-PETER MUELLER
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BINGER STRASSE 173
D-55216 INGELHEIM AM RHEIN, GERMANY
011-49-61-32-77-2414
AND
KLAUS H. JANDER, ESQ.
CLIFFORD CHANCE ROGERS & WELLS LLP
200 PARK AVENUE
NEW YORK, NY 10166
(212) 878-8000
------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
JUNE 5, 2000
------------------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition that is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the
following box / /
Note. Schedules filed in paper format should include a signed original
and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for
the other parties to whom copies are to be sent.
(Continued on following pages)
(Page 1 of 5 Pages)
<PAGE> 2
--------------------- -----------------
CUSIP NO. 464330 10 9 13D PAGE 2 OF 5 PAGES
--------------------- -----------------
--------------------------------------------------------------------------------
1. NAMES OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Boehringer Ingelheim International GmbH
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) / /
(b) / /
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. SOURCES OF FUNDS
OO
--------------------------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM
2(d) OR 2(e)
/ /
--------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Federal Republic of Germany
--------------------------------------------------------------------------------
7. SOLE VOTING POWER
2,030,107
NUMBER OF -------------------------------------------------------------
UNITS 8. SHARED VOTING POWER
BENEFICIALLY 0
OWNED BY -------------------------------------------------------------
EACH REPORTING 9. SOLE DISPOSITIVE POWER
PERSON 2,030,107
WITH -------------------------------------------------------------
10. SHARED DISPOSITIVE POWER
0
--------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,030,107
--------------------------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
/ /
--------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.5%
--------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON
CO
--------------------------------------------------------------------------------
<PAGE> 3
SCHEDULE 13D
FILED PURSUANT TO RULE 13d-1
OF THE GENERAL RULES AND REGULATIONS UNDER
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
This Amendment No. 3, which relates to shares of the common stock, par
value $0.001 per share (the "Common Stock") of Isis Pharmaceuticals, Inc. (the
"Issuer") and is being filed by Boehringer Ingelheim International GmbH
("Boehringer"), supplements and amends the statement on Schedule 13D, originally
filed with the Commission on July 28, 1995, as amended by Amendment No. 1, filed
with the Commission on December 23, 1996 and Amendment No. 2, filed with the
Commission on September 2, 1999.
ITEM 5. INTEREST IN THE SECURITIES OF THE ISSUER.
Item 5 is hereby amended to read in its entirety as follows:
(a) Beneficial Ownership: 2,030,107
Percentage Ownership: 5.5%
(b) Sole Voting Power: 2,030,107
Shared Voting Power: -0-
Sole Dispositive Power: 2,030,107
Shared Dispositive Power: -0-
(c) Recent Transactions: The following table sets forth sales
of shares of Common Stock by
Boehringer since September 2, 1999.
Such sales were effected on the open
market over the Nasdaq Stock Market
by a broker.
<TABLE>
<CAPTION>
APPROXIMATE PRICE
AMOUNT OF PER SHARE
DATE SHARES (exclusive of commissions)
<S> <C> <C>
3/23/00 10,000 $18.0688
3/29/00 20,000 $13.9263
3/30/00 20,000 $13.6075
4/3/00 20,000 $14.0000
4/5/00 20,000 $12.5125
4/5/00 20,000 $11.3388
4/6/00 40,000 $14.7729
4/7/00 21,600 $15.6079
4/11/00 3,800 $14.0000
4/12/00 20,000 $13.0000
5/2/00 20,000 $12.0775
5/3/00 20,000 $11.1016
5/4/00 9,600 $11.5078
5/5/00 20,000 $11.5000
5/15/00 20,000 $10.0109
5/16/00 20,000 $10.2538
5/18/00 20,000 $10.5141
5/19/00 6,600 $10.5000
5/22/00 1,900 $10.6140
6/2/00 20,000 $10.0863
6/5/00 9,000 $11.2688
6/5/00 20,000 $10.2500
</TABLE>
<PAGE> 4
(d) Right to Receive Dividends: Not Applicable
(e) Ownership below 5%: Not Applicable
<PAGE> 5
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: June 8, 2000
BOEHRINGER INGELHEIM INTERNATIONAL GmbH
By: /s/ Mueller
Name: Mr. Mueller
Title: Authorized Signatory
By: /s/ Joos
Name: Mr. Joos
Title: Authorized Signatory
